Recent Updates — MSCLF

Satellos Bioscience Inc. reported unaudited financial results for the six months ended June 30, 2026, posting a net loss of $21.49 million ($1.09 per share) compared to $11.75 million in the prior year period. The increase was driven by higher research and development expenses of $16.95 million for clinical advancement of SAT-3247 and general and administrative costs rising to $5.26 million due to Nasdaq listing requirements. Total assets grew to $65.77 million, supported by a February 2026 equity offering that raised approximately $51.9 million net of costs. The company also announced the initiation of its Phase 2 BASECAMP trial for Duchenne muscular dystrophy and received FDA Fast Track designation for SAT-3247 in June 2026. Satellos Bioscience Inc. is a clinical-stage biotechnology company developing small molecule drugs to treat degenerative muscle diseases.

Satellos Bioscience reported six-month interim TRAILHEAD data for SAT-3247 in adults with Duchenne Muscular Dystrophy (DMD). Results demonstrated reduced muscle fat fraction, increased effort, stable strength, lower creatine kinase (CK) levels, and a favorable safety profile. The company operates in the biotechnology industry and develops therapies for muscle-wasting diseases.